To Study the Safety and Efficacy of Autologous Bone Marrow Stem Cells in Patients With Spinal Cord Injury

Spinal Cord Injury Clinical Trial

— ABSCI  

Official title:

To Study the Safety and Efficacy of Autologous Bone Marrow Stem Cells in Patients With Spinal Cord Injury (SCI)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01730183
• Other study ID #: TPSC/POC/BMSC/SCI
• Status: Recruiting
• Phase: Phase 1/Phase 2
• First received: November 15, 2012
• Last updated: November 15, 2012
• Start date: November 2012
• Est. completion date: November 2014

Study information

• Verified date: November 2012
• Source: Max Institute of Neurosciences
• Contact: Yashbir Dewan, MS, MCh
• Phone: +91-8800255922
• Email: dr.ydewanneuro[@]gmail.com
• Is FDA regulated: No
• Health authority: India: Indian Council of Medical Research
• Study type: Interventional

Clinical Trial Summary

This is a Phase I/II, multicenter, prospective, non-randomized, open label study to evaluate the safety/efficacy of autologous bone marrow-derived stem cell transplantation in spinal cord injury patients.

Description:

Spinal cord injury (SCI) is a traumatic disorder resulting in a functional deficit that usually leads to severe and permanent paralysis and the projected data related to the burden of spinal cord injuries across the globe is quite alarming. Pharmacological and rehabilitation therapies to SCI have got limited effect. There is definitely an urgent need for finding different methods of treatment for these patients who cannot undergo established modalities of treatment or these have been tried unsuccessfully. Another promising therapeutic approach for SCI is "Stem cell transplantation". Bone marrow derived stem cells have been shown to promote anatomical and functional recovery in animal models of SCI by promoting tissue sparing, axonal regeneration, and remyelination. In our present study, we want to evaluate the safety and efficacy of autologous bone marrow derived stem cells surgically transplanted intrathecally into patients with spinal cord injury.

Other known NCT identifiers

• NCT01490242

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Traumatic injury of the spinal cord (below C5 level) occurring within 6 months to 8 years prior to treatment, resulting in a sustained and complete / Partial loss of sensory and motor function below the injury (ASIA Category A, B and C ).

2. Confirmation spinal cord injury level (Patients with complete or partial transection/damage by MRI).

3. Those provide fully informed consent.

4. The level of spinal cord injury must be below C4.

Exclusion Criteria:

1. Spinal vertebral instability.

2. Major concurrent medical illness (e.g. carcinoma, auto-immune disease,)

3. ASIA Impairment Scale category other than D & E.

4. Lactating and pregnant women.

5. Syringomyelia is also an exclusion criterion but an exemption can be made for a patient with a stable syrinx.

6. Platelet count greater than 100 thousand/µl at screening.

7. Hematocrit less than 30% prior to bone marrow aspiration.

8. Patients with major and current psychiatric illness.

9. Significant traumatic brain injury associated with the spinal cord injury.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Spinal Cord Injuries
• Spinal Cord Injury

Intervention

Other:
• Bone marrow derived stem cells
Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.

Locations

Country	Name	City	State
India	Max Super speciality Hospital	Dehradun	Uttrakhand

Sponsors (1)

Lead Sponsor	Collaborator
Max Institute of Neurosciences

Country where clinical trial is conducted

India, 

References & Publications (1)

Geffner LF, Santacruz P, Izurieta M, Flor L, Maldonado B, Auad AH, Montenegro X, Gonzalez R, Silva F. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008;17(12):1277-93. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events as a measure of safety and tolerability.	The measure is the number of adverse events following intrathecal administration of autologous bone marrow derived stem cells in spinal cord injury patients.	18 months	Yes
Secondary	Significant improvement in the ASIA scores by the assessment motor, sensory and sphincteric function.	Improvement in the functional Independence as measured by Spinal Cord Independence Measure (SCIM III). [ Time Frame: Baseline and 18 months ] [ Designated as safety issue: No ]; Improvement in the pain sensation score as measured by Bryce/Ragnarsson SCI pain taxonomy (BR-SCI-PT). [ Time Frame: Baseline and 18 months ] [ Designated as safety issue: No ]; Significant Changes in the muscle tone as indicated by Modified Ashworth Scale (MAS). [ Time Frame: Baseline and 18 months ] [ Designated as safety issue: No ]; Improvement in the Clinical Outcome Variable Scale (COVS) score. [ Time Frame: Baseline and 18 months ] [ Designated as safety issue: No ]	18 months	No